Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22042405 | 0.80 | MEN1 (0.33) | KMT2AMEN1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL31092635 | 0.80 | ITGB2 (0.41) | KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL23904934 | 0.80 | ITGB2 (0.41) | KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL31092643 | 0.80 | MEN1 (0.33) | KMT2AMEN1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL30790754 | 0.78 | HRH3 (0.34) | KMT2AMEN1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL16769737 | 0.76 | MEN1 (0.56) | KMT2AMEN1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL32677968 | 0.74 | CHRM4 (0.35) | KMT2AMEN1SMN1; SMN2MAPTLMNA | |
| SCHEMBL32677965 | 0.74 | CHRM4 (0.35) | KMT2AMEN1SMN1; SMN2MAPTLMNA | |
| SCHEMBL22042357 | 0.69 | MEN1 (0.32) | KMT2AMEN1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL12639925 | 0.69 | LMNA (0.76) | KMT2AMEN1SMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055108-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | HUTCHMED LTD (CN) | 2026-02-26 | — | — | US | disclosed |
| EP-4581032-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | HUTCHMED Limited (CN) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024046457-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | HUTCHMED LIMITED (CN) | 2024-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055108-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | CBR1, CNR1, CBR3 | KMT2A 3074/4885MEN1 2652/4885SMN1; SMN2 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.